Kyowa Hakko Kogyo Co., Ltd.

Cephalon, Inc.

Kyowa Hakko Kogyo

Hiromitsu Saito

Makoto Morimoto

Eiji Kobayashi

Satoru Nagamura

Masaji Kasai

Chikara Murakata

Katsushige Gomi

Hiroshi Sano

Tadashi Ashizawa

Yutaka Kanda

Tadashi Hirata

James C Kauer

Michael E Lewis

Yuzuru Matsuda

Yoichi Uosaki

Akira Sato

Nicola T Neff

Marcie A Glicksman

Jill M Roberts-Lewis

Fumihiko Kanai

Masami Kaneko

Motoo Yamasaki

Akira Asai

Nobuo Hanai

Toshiyuki Suzawa

Masami Okabe

Nobuhiro Nakamizo

Keiichi Takahashi

Takehiro Ogasa

So Ohta

Nobuyoshi Amishiro

Youichi Uosaki

Shigeo Katsumata

Uichiro Kimura

Akihiko Okamoto

Hiroyuki Ishida

Tsutomu Akama

Yutaka Saito

Mitsuru Takahashi

Koji Yamada

Yutaka Saitoh

Shiro Akinaga

Hiroshi Kase

Isao Kawamoto

Tatsuya Tamaoki

Shigeto Kitamura

Toru Yasuzawa

Takao Iida

Isami Takahashi

Kimihisa Ueno

Shun-ichi Ikeda

Soichiro Sato

Yukiteru Mimura

Akira Mihara

Shinji Tomioka

Yoshiaki Masuda

Tatsuhiro Ogawa

Yuichi Takahashi

Yasushi Shida

Shingo Kakita

Tohru Yasuzawa

Toshimitsu Takiguchi

Yoshimi Honma

Genkichi Ishikawa

Michio Ichimura

Masahiko Kinugawa

Junji Kanazawa

Shun-Ichi Ikeda

Kimihito Sasaki

Etsuko Nukui

Teruo Kishi

Kenichi Muroi

Kazuyo Sugiyama

The present invention relates to a toxin conjugate in which a residue derived from a compound having an affinity for a target cell is bound to a toxin through a spacer comprising polyalkylene glycol and dipeptide.

Toxin conjugates

The present invention relates to propenone derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR.sup.5 (wherein Y represents S or O; and R.sup.5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R.sup.2 and R.sup.3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R.sup.2 and R.sup.3 are combined to form substituted or unsubstituted methylene or ethylene; R.sup.4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.

Propenone derivatives

The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Protein kinase inhibitors for treatment of neurological disorders

Protein kinase inhibitors for treatmen of neurological disorders

DC 107 derivatives and treatment methods

DC-89 derivatives

Pyrrolo-indole derivatives

K-252a derivatives for treatment of neurological disorders

Process for producing indolocarbazole derivatives

Phospholipase C-inhibiting peptides

5-Aminoflavone derivatives represented by the formula (I): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are the same or different and represent hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, halogen-substituted or unsubstituted lower alkanoyl or lower alkoxycarbonyl, X.sup.1, X.sup.2, Y.sup.1 and Y.sup.2 are the same or different and represent hydrogen, halogen or lower alkyl, at least one of X.sup.1 and X.sup.2 represents halogen or lower alkyl, X.sup.3 represents hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, halogen, hydroxy, substituted or unsubstituted lower alkoxy, NR.sup.5 R.sup.6 (wherein R.sup.5 and R.sup.6 are the same or different and represent hydrogen, or substituted or unsubstituted lower alkyl, or R.sup.5 and R.sup.6 are taken together to form a heterocyclic group containing the nitrogen atom in the ring), lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, carboxy, lower alkoxycarbonyl, lower alkanoyl, adizo, cyano, substituted or unsubstituted carbamoyl or lower alkylthiothiocarbonyl: or pharmaceutically acceptable salts thereof.

5-aminoflavone derivatives

The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. Also, a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Selected protein kinase inhibitors for the treatment of neurological

Disclosed is a process for producing a staurosporine derivative represented by Formula (I): Q is defined as in specification: ##STR1## The staurosporine derivative (I-1) possesses selective protein kinase C-inhibitory and cell growth-inhibiting activities, and platelet-increasing activity.

Process for producing staurosporine derivatives

Growing community of inventors

Mishima, Japan

Hiromitsu Saito